XOMA Royalty (XOMA) Accumulated Expenses (2010 - 2026)
XOMA Royalty (XOMA) reported Accumulated Expenses of $378000.0 for Q1 2026, down 12.9% on a YoY basis from $434000.0 in Q1 2025, and down 96.18% sequentially from $9.9 million in Q4 2025.
XOMA Royalty (XOMA) Accumulated Expenses (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Accumulated Expenses data on file, last reported at $378000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 12.9% year-over-year to $378000.0; the trailing twelve-month figure through Mar 2026 stood at $378000.0 (down 12.9% YoY), and the FY2025 full-year result was $9.9 million, up 71.85% from the prior year.
- Accumulated Expenses declined to $378000.0 in Q1 2026, from $9.9 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $9.9 million in Q4 2025 to a low of $378000.0 in Q1 2026.
- A 5-year average of $2.8 million and a median of $1.9 million in 2023 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses soared 616.61% in 2023 and plunged 78.8% in 2024, its largest moves.
- Tracing XOMA's Accumulated Expenses over 5 years: stood at $562000.0 in 2022, then surged by 392.53% to $2.8 million in 2023, then jumped by 107.8% to $5.8 million in 2024, then jumped by 71.85% to $9.9 million in 2025, then plunged by 96.18% to $378000.0 in 2026.
- Business Quant data shows XOMA's Accumulated Expenses at $378000.0 in Q1 2026, $9.9 million in Q4 2025, and $663000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 378,000.00 |
| Dec 31, 2025 | 9.89 Mn |
| Sep 17, 2025 | 663,000.00 |
| Jun 30, 2025 | 5.41 Mn |
| Mar 31, 2025 | 434,000.00 |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 6.13 Mn |
| Dec 31, 2022 | 562,000.00 |
| Sep 30, 2022 | 461,000.00 |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 855,000.00 |
| Dec 31, 2021 | 525,000.00 |
| Sep 30, 2021 | 1.33 Mn |
| Jun 30, 2021 | 466,000.00 |